I used to think of the heart and the kidneys as roommates who mostly keep to themselves: one pumps, one filters, they pass each other in the hallway of the bloodstream and otherwise mind their own business. That picture is wrong, and European cardiologists just rebuilt a rulebook around exactly how wrong it is. Their fix opens with a urine test that costs almost nothing. Where it sends you next is a drug pathway that does not come cheap, written by a guideline panel where most of the authors take industry money. Both of those things are true at once.

At the ESC Congress in early September, the European Society of Cardiology and the European Renal Association released their first guideline built entirely around the collision of heart disease and chronic kidney disease, published in the European Heart Journal. The instruction is blunt: screen every patient with cardiovascular disease for kidney damage at the moment of diagnosis, a blood test for filtration rate and a urine test for albumin, then start treatment early. Task-force co-chair Kevin Damman said kidney disease can accelerate heart disease and the reverse, pushing patients toward cardiac events and dialysis “much earlier in life.” Across Europe, roughly 100 million people already carry the kidney half of that equation.

So here is the question I kept circling: why do the two organs drag each other down? For decades the default answer was starvation. A weakening heart pumps less blood forward, the kidney downstream gets shortchanged, filtration falls. Clean story, and not entirely wrong. But it was missing the bigger half. What has emerged as a major and long-underappreciated driver runs the other direction, and it is a plumbing problem. When a congested heart cannot keep up, pressure backs up through the veins, all the way into the renal veins that drain the kidney. And because the kidney sits inside a tight fibrous capsule with nowhere to swell, that rising back-pressure squeezes the filtering units from the outside and chokes off filtration.

Wait, so the kidney is not going hungry, it is getting crushed? That reordered the whole picture for me. Studies have found that central venous pressure, the back-pressure in the system, tracks with worsening kidney function more closely than how much blood the heart is actually pumping. The squeezed kidney then releases hormones that make the heart strain harder, which lifts the pressure again, and around it goes.

Once you see that, catching it early is obviously smart. The urine albumin-to-creatinine ratio is one of the cheapest, least invasive tests in medicine, a signal that shows up in the urine long before a patient feels a thing. On the screening itself I have no argument. Finding quiet kidney damage in a heart patient before it turns into dialysis is one of the best uses of a cheap test there is.

Here is where I get uneasy. Look at who wrote this guideline, and where “treat early” actually points you. An analysis of major ESC guidelines found that more than 80 percent of the writers carried a direct financial tie to industry, most often personal payments: speaker fees, consulting, advisory-board money. A companion review of European cardiovascular guidelines found that 42 percent of the studies behind the drug recommendations were industry-funded. These are not outsiders raising an inconvenient question. They are the guideline authors themselves, four-fifths of them on some company’s payroll, recommending that doctors screen every heart patient and start the drugs sooner.

GUIDELINE AUTHORS WITH INDUSTRY TIES
80%
of ESC guideline writers
Share of major-ESC-guideline authors reporting a direct financial conflict of interest. Source: TCTMD analysis of ESC guideline writers

I want to be fair about the drugs, because the lazy move would be to pretend they do not work. They work. The early-treatment list leans on SGLT2 inhibitors, and the trial evidence is strong. EMPA-KIDNEY randomized 6,609 patients with chronic kidney disease; those on empagliflozin had roughly a 28 percent lower risk of kidney disease progression or cardiovascular death, a hazard ratio of 0.72 (95 percent CI 0.64 to 0.82), and their filtration declined more slowly than the placebo group’s. DAPA-CKD, testing dapagliflozin, landed a hazard ratio of 0.61 (95 percent CI 0.51 to 0.72) on its primary kidney endpoint. Large, randomized, the same direction of effect in two separate trials. If the drugs ease that back-pressure before it wrecks a kidney, that counts for a lot.

But follow the money, because the authors’ own ledgers give you every reason to. “Screen everyone and start early” is about the most market-expanding sentence you can write in medicine. Then look at the timing. Branded empagliflozin, sold as Jardiance, still has no U.S. generic and runs around 600 dollars a month. Dapagliflozin, sold as Farxiga, only got its first true generic in April 2026; the generic can run near 93 dollars a month against 550-plus dollars for the brand. A heavily conflicted guideline panel pushing “broad and early” right as the cheapest version finally lands is exactly the pattern worth watching. The biology is not fake. But the same sentence that helps a patient also writes a very large check to whoever still holds the patent.

SGLT2 COST PER MONTH
around 600dollars
Jardiance (brand)
550-plusdollars
Farxiga (brand)
near 93dollars
Generic dapagliflozin
U.S. monthly prices; the first true generic dapagliflozin arrived in April 2026. Source: GoodRx; Network Health

So the honest read holds two things at once. The screening is the gift: a cheap urine test that catches a brutal feedback loop while there is still time to interrupt it. The drug funnel is the business: a lifelong branded-medication pathway, recommended for every heart patient in Europe, by authors most of whom take industry money.

If it were my heart, I would ask for the urine test tomorrow, because a failing kidney hides well and the test costs almost nothing. But I would also ask my doctor whether a generic sits on that early-start list and fits my diagnosis, I would take the generic when the evidence matches my case, and I would not sign up for the branded version for life without first asking who paid the people who told me to.

Sources

  1. European Society of Cardiology – new ESC/ERA guidelines recommend all heart-disease patients be tested for kidney disease (Sept 2026)
  2. European Heart Journal – 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease (advance article)
  3. ScienceDaily – Heart disease and kidney disease can fuel each other; new guidelines aim to break the cycle
  4. Methodist DeBakey Cardiovascular Journal – The Kidney in Heart Failure: The Role of Venous Congestion
  5. TCTMD – Roughly 80% of ESC guideline writers have financial conflicts of interest
  6. PMC – Conflicts of interest among authors and studies behind European cardiovascular guidelines
  7. New England Journal of Medicine – EMPA-KIDNEY: Empagliflozin in Patients with Chronic Kidney Disease
  8. New England Journal of Medicine (via PubMed) – DAPA-CKD: Dapagliflozin in Patients with Chronic Kidney Disease
  9. GoodRx – Farxiga vs. Jardiance SGLT2-inhibitor price comparison
  10. Network Health – first generic dapagliflozin arrives, prices drop (May 2026)